What is Global Age-Related Macular Degeneration (AMD) Therapeutics Market?
The Global Age-Related Macular Degeneration (AMD) Therapeutics Market is a specialized sector within the broader pharmaceutical industry. It focuses on the development and distribution of treatments for Age-Related Macular Degeneration (AMD), a medical condition that affects the eyes, particularly in older adults. AMD is a leading cause of vision loss, impacting millions of people worldwide. The market for AMD therapeutics is driven by the increasing prevalence of the disease, advancements in medical technology, and the growing global elderly population. The market encompasses a range of products, including drugs and medical devices, used in the treatment and management of AMD. These products are developed and manufactured by pharmaceutical companies and are distributed to healthcare providers, such as hospitals and clinics, for use in patient care. The market is also influenced by regulatory policies, healthcare spending, and the ongoing research and development efforts in the field of ophthalmology.
Wet AMD, Dry AMD in the Global Age-Related Macular Degeneration (AMD) Therapeutics Market:
Age-Related Macular Degeneration (AMD) is categorized into two types: Wet AMD and Dry AMD. Wet AMD is less common but more severe, characterized by the growth of abnormal blood vessels under the macula, leading to rapid and severe vision loss. On the other hand, Dry AMD is more common and less severe, characterized by the thinning of the macula over time. The Global AMD Therapeutics Market caters to both these types, with different therapeutic approaches. For Wet AMD, treatments aim to stop the growth of abnormal blood vessels, often through injections of anti-VEGF drugs. For Dry AMD, there is currently no cure, but certain vitamins and minerals can help slow the progression. The market for these therapeutics is vast, with numerous pharmaceutical companies involved in the development and distribution of these treatments. The market dynamics for Wet and Dry AMD therapeutics are influenced by factors such as the prevalence of the disease, the availability and effectiveness of treatments, and the ongoing research and development efforts in this field.
Hospital, Clinic, Research Institute, Other in the Global Age-Related Macular Degeneration (AMD) Therapeutics Market:
The Global Age-Related Macular Degeneration (AMD) Therapeutics Market plays a crucial role in various healthcare settings, including hospitals, clinics, research institutes, and others. In hospitals and clinics, AMD therapeutics are used in the treatment and management of patients suffering from this disease. These healthcare facilities rely on the supply of these therapeutics to provide effective care to their patients. On the other hand, research institutes use these therapeutics in their studies and trials, contributing to the advancement of knowledge and the development of new treatments in the field of AMD. Other areas where these therapeutics are used include home healthcare and long-term care facilities, where they are used in the ongoing care and management of patients with AMD. The usage of AMD therapeutics in these various areas is influenced by factors such as the prevalence of the disease, the availability and accessibility of treatments, and the healthcare policies and practices in place.
Global Age-Related Macular Degeneration (AMD) Therapeutics Market Outlook:
The market outlook for the Global Age-Related Macular Degeneration (AMD) Therapeutics Market is promising. In 2023, the market was valued at US$ 7725.7 million and is projected to reach US$ 11400 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast period from 2024 to 2030. This growth is reflective of the broader trends in the global pharmaceutical market, which is valued at 1475 billion USD in 2022 and is expected to grow at a CAGR of 5% over the next six years. The chemical drug market, a subset of the pharmaceutical market, is also expected to see growth, increasing from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. These trends indicate a positive trajectory for the AMD Therapeutics Market, driven by factors such as the increasing prevalence of AMD, advancements in medical technology, and the growing global elderly population.
| Report Metric | Details |
| Report Name | Age-Related Macular Degeneration (AMD) Therapeutics Market |
| Accounted market size in 2023 | US$ 7725.7 million |
| Forecasted market size in 2030 | US$ 11400 million |
| CAGR | 5.8% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Amgen Inc., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc. |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
